Guidance of marketing authorizations for Advanced Therapy Medicinal Products (ATMPs) in The USA The EU and JAPAN for a pre-requisite in Thailand

Main Article Content

Patcharaphun kidpun

Article Details

How to Cite
1.
kidpun P. Guidance of marketing authorizations for Advanced Therapy Medicinal Products (ATMPs) in The USA The EU and JAPAN for a pre-requisite in Thailand. TFDJ [Internet]. 2023 Aug. 3 [cited 2024 Apr. 13];30(2):5-18. Available from: https://he01.tci-thaijo.org/index.php/fdajournal/article/view/265168
Section
Review Article
Author Biography

Patcharaphun kidpun, Medicines Regulation Division, Food and Drug Administration

Regulation Division, Food and Drug Administration 88/24 Tambon Talad Khwan, Amphoe Mueang Nonthaburi Nonthaburi 11000, Thailand

References

สำนักงานคณะกรรมการอาหารและยา. แนวทางการขึ้นทะเบียนตำรับยาที่เป็นผลิตภัณฑ์การแพทย์ขั้นสูง ชนิดผลิตภัณฑ์เซลล์บำบัด [อินเทอร์เน็ต]. 2561 [เข้าถึง เมื่อ 25 ม.ค. 2562]; เข้าถึงได้จาก: http://www.fda.moph.go.th/sites/drug/Shared%20Documents/Law04-Notification-ThFDA/FDA-20180510.pdf

Hanna E, Rémuzat C, Auquier P, Toumi M. Advanced therapy medicinal products: current and future perspectives. Journal of market access health policy 2016;4(1):310-36.

Alliance for Regenerative Medicine. State of the Industry [Internet]. 2019 [cited 2019 May 29]. Available from: https://alliancerm.org/publication/q3-2019-data-report/

Prabhasawat P, Ekpo P, Uiprasertkul M, Chotikavanich S, Tesavibul N. Efficacy of cultivated corneal epithelial stem cells for ocular surface reconstruction. Clin Ophthalmol 2012;6:1483-492.

Prasongtanakij S, Anurathapan U, Vanichapol T, et al. Production and characterization of haploidentical CD19 CAR T cells: validated to induce a continuous complete remission in a patient with relapsed refractory B-cell ALL [published online ahead of print, 2020 Sep 24]. Asia Pac J Clin Oncol 2020;18(1):44-51.

European Medicines Agency. GUIDELINES on Good Clinical Practice specific to Advanced Therapy Medicinal Products [Internet]. 2019 [cited 2019 May 19]. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/atmp_guidelines_en.pdf

European Medicines Agency. Draft Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials [Internet]. 2019 [cited 2019 May 10]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy_en.pdf

United State Food and Drug Administration. Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products [Internet]. 2015 [cited 2019 May 9]. Available from: https://www.fda.gov/media/106369/download

European Medicines Agency. Regulation (EC) No 1394/2007 Of The European Parliament And Of The Council [Internet]. Official Journal of the European Union. 2007 [cited 2019 May 9]. Available from: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF

United State food and drug administration. Cellular & Gene Therapy Products [Internet]. 2019 [cited 2019 Jun 10 ]. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products

Azuma K. Regulatory Landscape of Regenerative Medicine in Japan. Current Stem Cell Reports 2015;1(2):118 - 28.

Okada K, Koike K, Sawa Y. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan. Regen Ther 2015;1:80-3.

Nagai S. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan. Int J Mol Sci. 2019 3;20(15):3801.

United state Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics [Internet]. 2014 [cited 2019 Jan 24] Available from: https://www.fda.gov/media/86377/download

The European Medicines Agency. Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC) No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004. [Internet]. 2016. [cited 2019 Jan 24 ] Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-scientific application-practical-arrangements-necessary-implement-commission-regulation-ec/2006-conditional-marketing-authorisation-medicinal-products-human-use-falling_en.pdf

The European Medicines Agency. Accelerated Assessment [Internet]. [cited 2019 Jan 25 ] Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/accelerated-assessment

The European Medicines Agency. PRIME: priority medicines. [Internet]. [cited 2019 Jan 25] Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines

The European Medicines Agency. Pilot project on adaptive licensing. [Internet]. 2014. [cited 2019 Jan 25] Available from: http://www.ema.europa.eu/docs/en_GB/document_ library/Other/2014/03/WC500163409.pdf

The European Medicines Agency. Guidance for companies considering the adaptive pathways approach [Internet]. 2016 [cited 2019 Jan 25] Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-companies-considering-adaptive-pathways-approach_en.pdf

Ministry of Health, Labour, and Welfare. Strategy of SAKIGAKE. [Internet]. 2014. [cited 2019 Jan 24] Available from: https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/140729-01.html

Schothorst M V, Krijn J W, Oortwijn W S, Hoekman J, Coppens D. Study on the regulation of advanced therapies in selected jurisdictions. [Internet]. 2016 [cited 2019 May 9] Available from: https://ec.europa.eu/health//sites/health/files/human-use/docs/20147306_rfs_chafea_2014_health_24_060516.pdf

United State food and drug administration. Interactions with Office of Tissues and Advanced Therapies [Internet]. [updated 2022 Jun 23; cited 2023 May 20] Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/interactions-office-tissues-and-advanced-therapies

United state Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics [Internet]. 2014 [cited 2019 Jan 24] Available from: https://www.fda.gov/media/86377/download

Japan Pharmaceutical Manufacturers Association. INFORMATION ON JAPANESE REGULATORY AFFAIRS Regulatory Information Task Force Japan [Internet]. 2018 [cited 2019 Jan 25] Available from: http://www.jpma.or.jp/english/parj/whole.html

Okura H, Matsuyama AJJoSCR. History of development and regulations for regenerative medicines in Japan. J Stem Cell Res Ther 2017;7(1):1-7.

The European Medicines Agency. Guideline on procedures for the granting of a marketing authorisation under exceptional circumstances, pursuant to article 14 (8) of regulation (EC) no 726/2004. [Internet]. 2005. [cited 2019 Jan 24] Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-procedures-granting-marketing-authorisation-under-exceptional-circumstances-pursuant/2004_en.pdf

United State food and drug administration. Approved Cellular and Gene Therapy Products [Internet]. 2023 [cited 2023 May 20] [Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

Pharmaceutical and Medical Devices Agency. Review Reports: Regenerative Medical Products [Internet]. 2023 [cited 2023 May 20]. Available from: http://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html.

The European Medicines Agency. CAT quarterly highlights and approved ATMPs January 2023 [Internet]. 2023 [cited 2023 May 26]. Available from: https://www.ema.europa.eu/en/documents/report/cat-quarterly-highlights-approved-atmps-january-2023_en.pdf